Encouraging News for Peregrine Pharma - Analyst Blog

Peregrine Pharmaceuticals ( PPHM ) recently presented encouraging data related to immune-stimulatory mechanism of action of phosphatidylserine (PS)-targeting antibodies from preclinical studies and other ongoing studies. We note that the company's lead candidate, bavituximab, a PS-targeting monoclonal antibody, is being developed for multiple oncology indications.

Peregrine Pharma expects to initiate a phase III study on the candidate for the treatment of second-line non-small cell lung cancer (NSCLC) by the end of 2013. In May 2013, the U.S. Food and Drug Administration agreed on the design of the phase III registration trial on bavituximab for the treatment of second-line NSCLC.

The randomized, double-blind, placebo-controlled, phase III trial (n=600) will be conducted across the world among stage IIIB/IV non-squamous NSCLC patients, whose disease progressed after standard front-line treatment, with the primary endpoint being overall survival. The study will compare bavituximab in combination with Sanofi 's ( SNY ) Taxotere (docetaxel) to Taxotere alone.

We note that bavituximab is a key pipeline candidate at Peregrine Pharma. In addition to second-line NSCLC, bavituximab is being studied for other indications including front-line pancreatic cancer, breast, liver and rectal cancer.

We expect investor focus to remain on updates pertaining to bavituximab. The successful development and commercialization of bavituximab would be a major positive for Peregrine Pharma which currently has no approved drug.

Peregrine Pharma currently carries a Zacks Rank #3 (Hold). Stocks such as Actelion ( ALIOF ) and Gilead Sciences, Inc. ( GILD ) currently look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy).


GILEAD SCIENCES (GILD): Free Stock Analysis Report

PEREGRINE PHARM (PPHM): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More